Study on Allopregnanolone and Depression in Perimenopausal Women (NCT05329779) | Clinical Trial Compass
TerminatedPhase 4
Study on Allopregnanolone and Depression in Perimenopausal Women
Stopped: low enrollment
United States2 participantsStarted 2022-11-04
Plain-language summary
This study aims to identify how the progesterone metabolite allopregnanolone affects behavior and neurobiology that may underlie perimenopausal depression.
Who can participate
Age range40 Years – 60 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy perimenopausal women ages 40 to 60 years
* Depressive symptoms
* Able to read Arabic numerals and perform simple arithmetic
* Able to provide written informed consent
Exclusion Criteria:
* Use of medications to treat depression
* Systemic hormone therapy
* Contraindicated medications with brexanolone
* Other psychiatric illnesses that are considered to be primary
* Current suicidal ideation
* Active substance use disorders
* Unstable medical conditions
* Obstructive sleep apnea or other primary sleep disorders
* Abnormal hepatic and renal function
* Known allergy to progesterone, exogenous allopregnanolone, or brexanolone
* History of head injury resulting in loss of consciousness \> 20 min
* Inability to comply with barrier contraceptive methods
* Known intellectual disability
* Investigator judgement that study participation constitutes substantial risk given medical or psychiatric condition
* Current or recent participation in clinical trial expected to interfere with risk of or interpretation of study data
* Inability to comply with study procedures
What they're measuring
1
Within-person Change in Score on the Ruminative Responses Scale